EADV Virtual 2020
These blogs and interview have been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content.
EADV Virtual
It’s time for EADV virtual, the 29th European Academy of Dermatology and Venereology (EADV) congress that explores new frontiers in dermatology and venereology. In these blog posts, we want to show you some of the exciting sessions on chronic spontaneous urticaria that are being discussed at EADV 2020. Find out more below.
Gain insight into the diagnosis and management of chronic spontaneous urticaria (CSU) as well as the impact of the COVID-19 pandemic in the sessions below from EADV virtual 2020.
Day one of the European Academy of Dermatology and Venereology (EADV) Virtual Congress 2020 was packed with a range of fascinating sessions on chronic spontaneous urticaria.
Explore the exciting research area of phenotypes, biomarkers and targeting the wheal in chronic spontaneous urticaria in the sessions below from EADV virtual 2020.
Day two of the European Academy of Dermatology and Venereology (EADV) Virtual Congress 2020 gave thought-provoking updates on a wide range of areas in chronic spontaneous urticaria.
Day three – exploring study outcomes for CSU
See the results of studies on chronic urticaria during pregnancy, the prevalence and predictors of angioedema, and comparing ligelizumab and omalizumab in the sessions below from EADV virtual 2020.
Too busy to make it to EADV virtual 2020? Don’t worry, find out about the best sessions and ePosters that came up over the three days in our brief recap below.
Sessions on chronic spontaneous urticaria (CSU) were an unmissable experience at the European Academy of Dermatology and Venereology (EADV) Virtual Congress 2020.
We catch up with Professor Marcus Maurer who reflects on the highlights of this year’s EADV Virtual Congress and discusses what the future may hold for the patients with chronic urticaria.
of interest
are looking at
saved
next event
This EADV 2020 content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content.